NeuroMetrix, Inc. (NURO) insider have most recently took part in a trading activity. On Jun 21, 2017 Higgins Thomas T, Senior Vice President, CFO bought 1,000 shares having total worth of $2,830 at the price of $2.83 per share, following the transaction a total of 15,963 shares owned by Higgins Thomas T. Before this latest buy, Higgins Thomas T purchased NURO at 5 other times during the past twelve months, for a total investment of $26,095 at an average of $2.03 per share.
The stock has experienced a total of 4 insider trades in the past three months. These trades include 4 buy trades. Furthermore, over the past 12 months , the stock was traded 10 times by insiders. an employee of the company was the buyer in 10 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of NeuroMetrix, Inc. (NURO) traded up 4.96% on Jun 21, 2017, hitting $2.83. 145,721 shares of the company’s stock traded hands. NeuroMetrix, Inc. has a 52 week low of $2.7 and a 52 week high of $16.61. The company’s market cap is $8 million.
NeuroMetrix, Inc. (NURO) last announced its earnings results on Apr 20, 2017. The company reported -0.40 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.49 by $0.09. The company had revenue of $4 million for the quarter, compared to the consensus estimate of $4 million. During the same quarter in the previous year, the company posted -1.00 earnings per share. The company’s revenue for the quarter was up 89% on a year-over-year basis.
|earnings per share||-0.40||-0.52||-0.76||-0.92||-1.00||-0.24||-0.26||-0.48||-0.25||-0.36|
NeuroMetrix, Inc was incorporated in Delaware in June 1996. The Company is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company develops and markets neurodiagnostic systems which typically consist of a medical device plus single-use biosensors or electrodes. Other accessories are also offered to its customers. Its initial product for diabetic neuropathy, NC-stat DPNCheck, was launched in September 2011. NC-stat DPNCheck is a fast, accurate, and quantitative nerve conduction test that is used to evaluate systemic neuropathies such as DPN. It is designed to be used by primary care physicians, endocrinologists, podiatrists and other clinicians at the point-of-care to objectively detect, stage, and monitor DPN. The device measures nerve conduction velocity and response amplitude of the sural nerve, a nerve in the lower leg and ankle. These parameters are recognized as sensitive and specific biomarkers of DPN. The Company also markets a medical device, which has been cleared by the FDA and which is used for the assessment of neuropathies such as carpal tunnel syndrome, diabetes, and sciatica. Its ADVANCE NCS/EMG System, or the ADVANCE System, which is a part of its legacy neurodiagnostics business, is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures. Its ADVANCE System is comprised of: (1) various types of electrodes and needles, (2) its ADVANCE device and related modules, and (3) a communication hub that enables the physician’s office to network their device to its servers for data archiving, report generation and other network services. The Company competes with CareFusion Corporation, Cadwell Laboratories, Inc., and Natus Medical Incorporated. The Company’s products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the regulations promulgated thereunder, as well as by other regulatory bodies in the United States and abroad.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018